Suraksha Diagnostic Limited has informed the Exchange regarding a press release dated May 28, 2025, titled ""Suraksha-Press Release Q4 & FY25".
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its first full-year results post-IPO. FY25 total income grew 15.2% year-on-year to ₹2,559.4 million, with EBITDA up 15.6% to ₹850.9 million (margin 33.8%) and profit after tax jumping 34% to ₹309.8 million. Q4 FY25 revenue grew a strong 17.4% YoY to ₹659.1 million, but EBITDA dipped 2.2% to ₹200.1 million as margins compressed to 30.7% from 37.1% a year ago, though Q4 PAT still rose 13.4% to ₹71.7 million. The company added 7 diagnostic centers during FY25 and plans 15-18 more in FY26, while also acquiring a ~63% controlling stake in Fetomat Wellness to enter genomic and prenatal medicine.
Strong double-digit full-year growth in revenue, EBITDA, and PAT reinforces the post-listing growth story, but the Q4 EBITDA margin compression is a watchpoint. Aggressive expansion plans and the Fetomat acquisition signal a growth-focused FY26, which should be positive for long-term investors but may keep near-term margins under pressure as new centers ramp up.